Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/dpp-iv-inhibition-enhances-the-antilipolytic-action-of-npy-in-human-O3Z4C6Ly0f
References (28)
-
K. Kos, A. Harte, S. James, D. Snead, J. O’Hare, P. McTernan, Sudhesh Kumar (2007)
Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass.American journal of physiology. Endocrinology and metabolism, 293 5
-
A. Brazma, P. Hingamp, John Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. Aach, W. Ansorge, C. Ball, H. Causton, T. Gaasterland, Patrick Glenisson, F. Holstege, Irene Kim, V. Markowitz, J. Matese, H. Parkinson, A. Robinson, Ugis Sarkans, S. Schulze-Kremer, Jason Stewart, Ronald Taylor, J. Vilo, M. Vingron (2001)
Minimum information about a microarray experiment (MIAME)—toward standards for microarray dataNature Genetics, 29
-
C. Gal, M. Lafontan, Danielle Raufaste, J. Marchand, B. Pouzet, P. Casellas, M. Pascal, J. Maffrand, G. Fur (2000)
Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytesFEBS Letters, 475
-
X. Chu, K. Bleasby, J. Yabut, Xiaoxin Cai, G. Chan, M. Hafey, S. Xu, A. Bergman, M. Braun, D. Dean, R. Evers (2007)
Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoproteinJournal of Pharmacology and Experimental Therapeutics, 321
-
C. Billington, J. Briggs, M. Grace, Allen Levine (1991)
Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.The American journal of physiology, 260 2 Pt 2
-
F. Pi‐Sunyer, A. Schweizer, D. Mills, S. Dejager (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.Diabetes research and clinical practice, 76 1
-
C. Eva, M. Serra, P. Mele, G. Panzica, A. Oberto (2006)
Physiology and gene regulation of the brain NPY Y1 receptorFrontiers in Neuroendocrinology, 27
-
A. Harte, P. McTernan, R. Chetty, S. Coppack, Jonathan Katz, Stephen Smith, Sudhesh Kumar (2005)
Insulin-Mediated Upregulation of the Renin Angiotensin System in Human Subcutaneous Adipocytes Is Reduced by RosiglitazoneCirculation, 111
-
Béatrice Sudre, P. Broqua, R. White, D. Ashworth, D. Evans, R. Haigh, J. Junien, M. Aubert (2002)
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.Diabetes, 51 5
-
E. Heymann, R. Mentlein (1984)
[Has dipeptidyl peptidase IV an effect on blood pressure and coagulation?].Klinische Wochenschrift, 62 1
-
P. Kalra, M. Dube, B. Xu, W. Farmerie, S. Kalra (1998)
Neuropeptide Y (NDY) Y1 Receptoe mRNA is Upregulated in Association with Transient Hyperphagia and Body Weight Gain: Evidence for a Hypothalamic Site for Concurrent Development of Leptin ResistanceJournal of Neuroendocrinology, 10
-
Z. Żukowska-Grójec, E. Karwatowska-Prokopczuk, W. Rose, J. Rone, Sharareh Movafagh, H. Ji, Y. Yeh, Wen‐Tien Chen, H. Kleinman, E. Grouzmann, D. Grant (1998)
Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium.Circulation research, 83 2
-
B. Burkey, Xia Li, Lori Bolognese, B. Balkan, M. Mone, M. Russell, T. Hughes, Pei-ran Wang (2005)
Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant RatsJournal of Pharmacology and Experimental Therapeutics, 315
-
L. Turtzo, R. Marx, M. Lane (2001)
Cross-talk between sympathetic neurons and adipocytes in cocultureProceedings of the National Academy of Sciences of the United States of America, 98
-
M. Jernås, J. Palming, K. Sjöholm, Eva Jennische, P. Svensson, B. Gabrielsson, Max Levin, Anders Sjögren, Mats Rudemo, Theodore Lystig, Björn Carlsson, Lena Carlsson, Malin Lonn (2006)
Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expressionThe FASEB Journal, 20
-
Gareth Williams, J. Harrold, D. Cutler (2000)
The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black boxProceedings of the Nutrition Society, 59
-
M. Labelle, Y. Boulanger, A. Fournier, S. St.-Pierre, R. Savard (1997)
Tissue-Specific Regulation of Fat Cell Lipolysis by NPY in 6-OHDA-Treated RatsPeptides, 18
-
E. Heymann, R. Mentlein (2005)
Beeinflußt Dipeptidylpeptidase IV Blutdruck und Gerinnung?Klinische Wochenschrift, 62
-
Alissa Langley, Terri Suffoletta, H. Jennings (2007)
Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 27
-
C. Nilsson, A. Westman, K. Blennow, R. Ekman (1998)
Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometryPeptides, 19
-
K. Wynne, S. Stanley, B. Mcgowan, S. Bloom (2005)
Appetite control.The Journal of endocrinology, 184 2
-
P. Valet, M. Berlan, M. Beauville, Franmois Crampes, J. Montastruc, M. Lafontan (1990)
Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein.The Journal of clinical investigation, 85 1
-
R. Bradley, Julia Mansfield, E. Maratos-Flier (2005)
Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes.Obesity research, 13 4
-
B. Ahrén, O. Schmitz (2004)
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 36 11-12
-
B. Chronwall, Z. Żukowska (2004)
Neuropeptide Y, ubiquitous and elusivePeptides, 25
-
I. Castan, P. Valet, N. Quideau, T. Voisin, L. Ambid, M. Laburthe, M. Lafontan, C. Carpéné (1994)
Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes.The American journal of physiology, 266 4 Pt 2
-
R. Mentlein (1999)
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptidesRegulatory Peptides, 85
-
L. Blonde, E. Klein, Jenny Han, B. Zhang, S. Mac, T. Poon, K. Taylor, M. Trautmann, Dennis Kim, D. Kendall (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes, 8
- Publisher
- Wiley
- Copyright
- Copyright © 2009 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 1462-8902
- eISSN
- 1463-1326
- DOI
- 10.1111/j.1463-1326.2008.00909.x
- pmid
- 19175376
- Publisher site
- See Article on Publisher Site
Abstract
Context: Dipeptidyl peptidase IV (DPP‐IV) inactivates the incretin hormone glucagon‐like peptide. It can also affect the orexigenic hormone neuropeptide Y (NPY1–36) which is truncated by DPP‐IV to NPY3–36, as a consequence NPY’s affinity changes from receptor Y1, which mediates the antilipolytic function of NPY, to other NPY receptors. Little is known whether DPP‐IV inhibitors for the treatment of type 2 diabetic (T2DM) patients could influence these pathways.
Journal
Diabetes Obesity & Metabolism – Wiley
Published: Apr 1, 2009
Keywords: ; ; ; ; ; ;